Aplagon is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for thromboinflammatory diseases, which are significant contributors to cardiovascular issues and mortality worldwide. Their lead therapeutic candidate, APAC, is a heparin proteoglycan mimetic that exhibits a unique triple-action mechanism, functioning as an antiplatelet, anticoagulant, and anti-inflammatory agent. This multifunctional approach allows APAC to specifically target vascular injury sites, effectively inhibiting thrombosis and inflammation while preserving normal hemostasis. The drug is designed for both local and systemic administration, making it versatile for various clinical applications, particularly in preventing complications associated with vascular surgeries and conditions like peripheral arterial occlusive disease.

The mechanism of action of APAC is characterized by its ability to bind to positively charged proteins exposed at arterial injury sites, enhancing blood circulation and modulating the interplay between coagulation and inflammation. This localized action minimizes systemic exposure, thereby reducing the risk of bleeding compared to traditional antithrombotic therapies. Aplagon's ongoing clinical trials, including the CHASE study, aim to evaluate the safety, tolerability, and biodistribution of APAC, with promising initial findings indicating its potential to address a wide range of thromboinflammatory conditions effectively.

Finland

Aplagon is a clinical stage biopharmaceutical company developing first-in-class therapeutics for thromboinflammatory diseases. These include thrombotic, inflammatory and fibrotic conditions. Aplagon was founded in 2009 and is based on the pioneering research performed by Prof. Riitta Lassila and associates at Wihuri Research Institute in Helsinki, Finland.

Aplagon

Company Details